FDA Initiates Transition to Non-Animal Testing Methods for Monoclonal Antibodies

The FDA's new approach emphasizes the use of New Approach Methodologies (NAMs), which include AI-based computational models and human cell-based laboratory tests, such as organoids and organ-on-a-chip systems. These methods aim to provide more accurate predictions of human responses to drugs, potentially reducing the reliance on animal models that may not fully replicate human physiology.

Implementation of this policy begins immediately for investigational new drug (IND) applications, where the inclusion of NAMs data is encouraged. Additionally, the FDA plans to utilize existing real-world safety data from other countries with comparable regulatory standards to assess drug efficacy.

FDA Commissioner Dr. Martin A. Makary highlighted the benefits of this transition, stating that leveraging AI-based modeling and human organ model-based lab testing can lead to safer treatments reaching patients more quickly and at lower costs. He emphasized that this approach is advantageous for both public health and ethical considerations.

Key aspects of the initiative include:

• Advanced Computer Simulations: Utilizing AI to model drug behavior and predict potential side effects, enhancing the accuracy of safety assessments.
• Human-Based Lab Models: Employing lab-grown human tissues to better understand drug interactions and toxicities specific to human biology.
• Regulatory Incentives: Encouraging the adoption of NAMs by streamlining the review process for applications that incorporate robust non-animal testing data.

This policy shift aligns with the FDA Modernization Act 2.0, enacted in 2022, which removed the mandatory requirement for animal testing in drug development, thereby promoting the use of alternative testing methods. Read the full test "FDA Announces Plan to Phase Out Animal Testing Requirement for Monoclonal Antibodies and Other Drugs" on the official FDA website.